Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

January 5, 2024

https://www.globenewswire.com/news-release/2024/01/05/2804581/0/en/Verrica-Pharmaceuticals-Announces-Last-Patient-Dosed-in-Part-2-of-Phase-2-Study-of-VP-315-a-Potential-First-in-Class-Oncolytic-Peptide-Based-Immunotherapy-for-the-Treatment-of-Basa.html

There are approximately 3-4 million diagnoses of basal cell carcinomas in the U.S. each year, with a high unmet need for new treatment options

Company reiterates lesion clearance data from Part 2 of Phase 2 expected in Q2 2024

Read more at globenewswire.com

Related news for (VRCA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.